ActualitésAssisté par IA

Kane Biotech’s Revyve™ Wound Gel Gains Health Canada Approval

Kane Biotech's revyve™ Antimicrobial Wound Gel gets Health Canada approval as a Class 2 medical device.

Par Simantini Singh Deo

Rédacteur principal de contenu

15 nov. 2024Updated Jun 26, 2025 · 2 min de lecture

Partager Ajouter comme source préférée

Kane Biotech’s Revyve™ Wound Gel Gains Health Canada Approval — https://www.progenacare.com/product/revyve/

Journalisme assisté par IA

Reviewed by Simantini Singh Deo, Rédacteur principal de contenu

Kane Biotech Inc. announced today that it has gained approval from Health Canada for its revyve™ Antimicrobial Wound Gel, now classified as a Class 2 medical device. With this approval, the company can begin promoting and selling the product across Canada immediately.

“We are excited to bring this much-needed product to Canada. Congratulations to the Kane Biotech team for achieving this important milestone and continuing to execute our strategic plan,” said Marc Edwards, President & CEO.

SujetsActualités

Written by

Simantini Singh Deo

Rédacteur principal de contenu

Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.